Atomo DiagnosticsASX:AT1 Current Ratio is 2.78 as of Dec. 2025, which is 77% below its 10-year median of 11.98. The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Atomo Diagnostics ranks better than 55.27% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Atomo Diagnostics's current ratio for the quarter that ended in Dec. 2025 was 2.78.
Atomo Diagnostics has a current ratio of 2.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for Atomo Diagnostics's Current Ratio or its related term are showing as below:
ASX:AT1'
s Current Ratio Range Over the Past 10 Years
Min: 2.78 Med: 11.98 Max: 59.07
Current: 2.78
During the past 6 years, Atomo Diagnostics's highest Current Ratio was 59.07. The lowest was 2.78. And the median was 11.98.
ASX:AT1's Current Ratio is ranked better than 55.27% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs ASX:AT1: 2.78
Atomo Diagnostics (ASX:AT1) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Atomo Diagnostics Current Ratio Related Terms
Atomo Diagnostics Current Ratio Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AT1 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Atomo Diagnostics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a Current Ratio of 2.78 as of Dec. 2025. This is 77% below median its historical median of 11.98. Over the past decade, Atomo Diagnostics' Current Ratio has ranged from 2.78 to 59.07. According to the industry distribution chart, Atomo Diagnostics ranks #382 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is Atomo Diagnostics' Current Ratio too high?
Atomo Diagnostics' current Current Ratio of 2.78 is 77% below median its 10-year median of 11.98. Over the past 10 years, this metric has ranged from a low of 2.78 to a high of 59.07. The Medical Devices & Instruments industry median Current Ratio is 2.49. Atomo Diagnostics' value of 2.78 is 11.9% above this industry median. Based on the distribution chart, Atomo Diagnostics ranks #382 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Atomo Diagnostics' Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #382 out of 854 companies for Current Ratio. This puts Atomo Diagnostics in the upper half of its industry. The industry median Current Ratio is 2.49. Atomo Diagnostics' value of 2.78 is 11.9% above this benchmark. Historically, Atomo Diagnostics' own Current Ratio has ranged from 2.78 to 59.07 over the past decade. While the company's 10-year median is 11.98 vs. the industry median of 2.49, Atomo Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atomo Diagnostics's current Current Ratio of 2.78 is 11.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current Current Ratio is 2.78, which is 77% below median its own 10-year median of 11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Current Ratio is 2.78, which is 77% below median its 10-year median of 11.98 and 11.9% above the Medical Devices & Instruments industry median of 2.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Current Ratio is 2.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 